The Lancet Oncology,

[Comment] Improving selection of individuals into lung cancer screening programmes

The results of the National Lung Screening Trial (NLST), first announced in November, 2010, showed a 20% decline in mortality with three rounds of screening.1 The NELSON study was presented at the International Association for the Study of Lung Cancer meeting and confirmed the benefit of screening.2 Work by James Hanley and colleagues3 utilised the NLST data and showed that continued annual screening could potentially lower mortality by as much as 30%. Current screening guidelines by the US Preventive...

The Lancet Oncology

01:30

[Articles] 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

Patients with lung cancer who quit 15 or more years before diagnosis and those who are up to 5 years younger than the age cutoff recommended for screening, but otherwise meet USPSTF criteria, have a similar risk of death to those individuals who meet all USPSTF criteria. Individuals in both subgroups could benefit from screening, as expansion of USPSTF screening criteria to include these subgroups could enable earlier detection of lung cancer and improved survival outcomes.

The Lancet Oncology

01:30